Section Arrow
ITOS.NASDAQ
- iTeos Therapeutics
Quotes are at least 15-min delayed:2024/10/31 19:15 EDT
Last
 8.45
-0.14 (-1.63%)
Day High 
8.835 
Prev. Close
8.59 
1-M High
10.22 
Volume 
687.96K 
Bid
8.3
Ask
8.51
Day Low
8.41 
Open
8.54 
1-M Low
8.48 
Market Cap 
313.72M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.94 
20-SMA 9.26 
50-SMA 12.16 
52-W High 18.75 
52-W Low 8.48 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.96/-7.41
Enterprise Value
318.53M
Balance Sheet
Book Value Per Share
18.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
12.60M
Operating Revenue Per Share
1.82
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.